These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 36773456

  • 1. 1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.
    Wang S, Shi JT, Wang XR, Mu HX, Wang XT, Xu KY, Wang QS, Chen SW.
    Bioorg Chem; 2023 Apr; 133():106412. PubMed ID: 36773456
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 3. Discovery of novel potent PI3K/mTOR dual-target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity.
    Yang Y, Sun X, Luo L, Peng R, Yang R, Cheng Z, Lv Y, Li H, Tang Q, Zhu W, Qiao D, Xu S.
    Arch Pharm (Weinheim); 2023 Dec; 356(12):e2300403. PubMed ID: 37840368
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li Z, Wang J, Li B, Hu Y, Dong B, Shen L, Ji J, Gao J, Zhang X.
    Cell Death Dis; 2018 Jan 26; 9(2):123. PubMed ID: 29374144
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ampelopsin induces MDA-MB-231 cell cycle arrest through cyclin B1-mediated PI3K/AKT/mTOR pathway in vitro and in vivo.
    Meng M, Yang Q, Ouyang Z, Yang Q, Wu X, Huang Y, Su Y, Chen S, Chen W.
    Acta Pharm; 2023 Mar 01; 73(1):75-90. PubMed ID: 36692465
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH.
    Cells; 2021 Oct 27; 10(11):. PubMed ID: 34831139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
    Mardanshahi A, Gharibkandi NA, Vaseghi S, Abedi SM, Molavipordanjani S.
    Mol Biol Rep; 2021 Aug 27; 48(8):1-14. PubMed ID: 34357550
    [Abstract] [Full Text] [Related]

  • 20. Preclinical Evaluation of a Fluorine-18 (18F)-Labeled Phosphatidylinositol 3-Kinase Inhibitor for Breast Cancer Imaging.
    Altine B, Gai Y, Han N, Jiang Y, Ji H, Fang H, Niyonkuru A, Bakari KH, Rajab Arnous MM, Liu Q, Zhang Y, Lan X.
    Mol Pharm; 2019 Nov 04; 16(11):4563-4571. PubMed ID: 31553879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.